DaVita (NYSE:DVA) Given New $164.00 Price Target at Barclays

DaVita (NYSE:DVA) had its price target boosted by Barclays from $150.00 to $164.00 in a research report report published on Thursday, Benzinga reports. They currently have an equal weight rating on the stock.

Other equities analysts have also recently issued reports about the company. UBS Group lifted their price target on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Bank of America boosted their target price on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. TD Cowen boosted their target price on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. Finally, Truist Financial boosted their target price on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $161.80.

DaVita Price Performance

Shares of DaVita stock opened at $139.81 on Thursday. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.12. The business’s 50 day simple moving average is $157.96 and its two-hundred day simple moving average is $145.97. The stock has a market capitalization of $11.46 billion, a P/E ratio of 15.08, a price-to-earnings-growth ratio of 0.82 and a beta of 0.87. DaVita has a one year low of $76.17 and a one year high of $168.50.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The company had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. DaVita’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period last year, the firm earned $2.85 earnings per share. Analysts forecast that DaVita will post 9.84 EPS for the current year.

Insider Buying and Selling

In related news, CEO Javier Rodriguez sold 32,176 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $155.93, for a total value of $5,017,203.68. Following the sale, the chief executive officer now directly owns 905,659 shares of the company’s stock, valued at $141,219,407.87. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other DaVita news, CFO Joel Ackerman sold 64,029 shares of the business’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total value of $9,928,336.74. Following the sale, the chief financial officer now directly owns 111,481 shares of the company’s stock, valued at approximately $17,286,243.86. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Javier Rodriguez sold 32,176 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $155.93, for a total value of $5,017,203.68. Following the completion of the sale, the chief executive officer now directly owns 905,659 shares in the company, valued at $141,219,407.87. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 173,482 shares of company stock valued at $27,387,069 over the last ninety days. Company insiders own 2.00% of the company’s stock.

Institutional Investors Weigh In On DaVita

Several hedge funds have recently added to or reduced their stakes in the stock. Financial Strategies Group Inc. boosted its holdings in DaVita by 19.2% in the third quarter. Financial Strategies Group Inc. now owns 3,135 shares of the company’s stock worth $507,000 after acquiring an additional 504 shares in the last quarter. QRG Capital Management Inc. boosted its holdings in DaVita by 5.0% in the third quarter. QRG Capital Management Inc. now owns 4,577 shares of the company’s stock worth $750,000 after acquiring an additional 216 shares in the last quarter. Asset Management One Co. Ltd. boosted its holdings in DaVita by 4.7% in the third quarter. Asset Management One Co. Ltd. now owns 19,629 shares of the company’s stock worth $3,218,000 after acquiring an additional 886 shares in the last quarter. Forum Financial Management LP bought a new stake in DaVita in the third quarter worth $221,000. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of DaVita by 16.4% during the third quarter. Janney Montgomery Scott LLC now owns 24,591 shares of the company’s stock valued at $4,031,000 after purchasing an additional 3,468 shares in the last quarter. 90.12% of the stock is owned by institutional investors.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.